Analysis of the key ligand receptor CADM1_CADM1 in the regulation of thyroid cancer based on scRNA-seq and bulk RNA-seq data

Abstract

IntroductionAdvanced papillary thyroid cancer (PTC) has a poor prognosis, 60~70% of which become radio iodine refractory (RAI-R), but the molecular markers that assess PTC progress to advanced PTC remain unclear. Meanwhile, current targeted therapies are badly effective due to drug resistance and adverse side effects. Ligand-receptor pairs (L/R pairs) play an important role in the interactions between tumor cells and other cells in the tumor microenvironment (TME). Nowadays, therapies targeting ligand-receptor pairs in the TME are advancing rapidly in the treatment of advanced cancers. However, therapies targeting L/R pairs applied to advanced PTC remains challenging because of limited knowledge about L/R pairs in PTC.MethodsWe screened the critical L/R pair: CADM1-CADM1 using 65311 single-cell RNA sequencing (scRNA-seq) samples from 7 patients in different stage of PTC and bulk RNA-seq datasets containing data from 487 tumor samples and 58 para-carcinoma samples. Moreover, the expression levels of CADM1-CADM1 was assessed by quantitative real time polymerase chain reaction (qRT-PCR) and the function was analyzed using Transwell immigration assay.ResultsWe found that CADM1_CADM1 could be regarded as a biomarker representing a good prognosis of PTC. In addition, the high expression of CADM1_CADM1 can strongly increase the sensitivity of many targeted drugs, which can alleviate drug resistance. And the results of qRT-PCR showed us that the expression of CADM1_CADM1 in PTC was down-regulated and overexpression of CADM1 could suppresses tumor cell invasion migration.ConclusionOur study identified that CADM1_CADM1 played an essential role in the progression of PTC for the first time and our findings provide a new potential prognostic and therapeutic ligand-receptor pair for advanced PTC.

Exploring the advances of single-cell RNA sequencing in thyroid cancer: a narrative review

“…Detailed analysis of scRNA-seq data from thyroid cancer cells has aided in the identification of novel biomarkers for PTC. Specifically, it has pointed out a critical LR pair biomarker, cell adhesion molecule 1 (CADM1)-CADM1, associated with a favourable prognosis in PTC [29]. Interestingly, the expression of CADM1-CADM1 was downregulated in PTC, and overexpression of CADM1 could inhibit tumour cell invasion and migration [29].…”

“…Specifically, it has pointed out a critical LR pair biomarker, cell adhesion molecule 1 (CADM1)-CADM1, associated with a favourable prognosis in PTC [29]. Interestingly, the expression of CADM1-CADM1 was downregulated in PTC, and overexpression of CADM1 could inhibit tumour cell invasion and migration [29]. CADM1-CADM1 was more highly expressed in younger populations under 50 years old and stage I, compared to stage II and older populations over 50 years old [29].…”

“…Interestingly, the expression of CADM1-CADM1 was downregulated in PTC, and overexpression of CADM1 could inhibit tumour cell invasion and migration [29]. CADM1-CADM1 was more highly expressed in younger populations under 50 years old and stage I, compared to stage II and older populations over 50 years old [29]. Furthermore, a distinct BRAF-like B subtype with prominent dedifferentiation-like thyrocytes, enriched CAFs, and a worse prognosis was identified [20].…”

PANoptosis in cancer, the triangle of cell death

“…Moreover, the study confirmed that radixin (RDX), the gene with the highest hazard ratio (HR) among the PANoptosis prognosis‐related genes, was prominently expressed in arterial endothelial cells (ECs). This investigation enriches our comprehension of the involvement of PANoptosis in breast cancer and offers promising new directions for breast cancer immunotherapy 135 …”

“…This investigation enriches our comprehension of the involvement of PANoptosis in breast cancer and offers promising new directions for breast cancer immunotherapy. 135…”